cisplatin + ifosfamide + vindesine

The combination of cisplatin, ifosfamide, and vindesine—commonly referred to as the VIP regimen—is a chemotherapy protocol used primarily for the treatment of advanced non-small cell lung cancer. Each component has a distinct mechanism of action: - Cisplatin is an alkylating agent that cross-links DNA, leading to DNA damage and apoptosis in rapidly dividing cells. - Ifosfamide is also an alkylating agent (oxazaphosphorine class) that requires hepatic activation; it induces cytotoxicity by forming DNA cross-links and inhibiting DNA synthesis. - Vindesine is a vinca alkaloid that inhibits microtubule formation by binding to tubulin, arresting cells in metaphase during mitosis. This regimen has demonstrated significant activity with manageable toxicity profiles in patients with good performance status suffering from advanced or metastatic non-small cell lung cancer[1]. The main toxicities are bone marrow suppression and gastrointestinal effects such as nausea and vomiting.

Other names

VIP